News for AbCellera Biologics Inc. (ABCL)

Revenue: Approximately $29 million for the year, primarily from research fees on partnered programs, compared to $38 million in 2023.Net Loss: Roughly $163 mil

Feb 27, 2025 / 10:00PM GMTOperator Good afternoon and welcome to Apelleus for full year 2024 business update conference call. My name is Tamia, and I will facil

AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and...

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 26.67% and 40.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $28.8 million for FY 2024, falling short of the annual estimate of $31.58 million.Net Loss: $162.9 million, an increase from the $146.4 million net lo

AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars,

AbCellera Biologics Inc (ABCL) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $7.58 million, and the earn

[url="]AbCellera[/url] (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call a

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc.

AbCellera and AbbVie expand oncology collaboration

VANCOUVER, British Columbia —

We recently published a list of the 12 Best Canadian Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where AbCellera Biologics Inc.

AbCellera Biologics Inc. shifts focus to developing wholly owned candidates and trades near net cash on its balance sheet. Find out why ABCL stock is a Hold.

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and...

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of -21.43% and 27.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

The following slide deck was published by AbCellera Biologics Inc.

VANCOUVER, British Columbia —

BIV’s 2023 list of fastest-growing companies highlights 100 B.C. companies that have seen extraordinary success increasing revenue over the past five years.

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.